In order to evaluate AML sensitivity to GSK3α/β gene silencing, we analyzed the publically available shRNA screening data in Project DRIVE16, which contains the cell viability data following shRNA gene silencing of various genes across 384 cancer cell lines. This evidence concerns the gene GSK3A and acute myeloid leukemia.